The preclinical outcomes of research by scientists from the City College of New York and TechnoVax, Inc. using animal models demonstrate favorable effects in developing a vaccine in opposition to the mosquito-borne Zika virus. The outcome had been announced via Tarrytown, NY-established TechnoVax, a biotechnology developer of novel vaccines whose proprietary virus-like particle (VLP) is the center of the research.
The ones who are collaborating for this research is CUNY School of Medicine at City College faculty, Paul Gottlieb and Linda Spatz, and Al Katz of the CCNY Physics Department together with TechnoVax.
Effect Of Zika Virus Vaccine
The VLP vaccine formulations being tested in animals not only have been good in eliciting protective antibodies with neutralizing activity identical to or greater than the activity in the serum of a patient who recovered from Zika contamination but also had been well tolerated and secure. Jose M. Galarza, TechnoVax CEO remarked, The ZIKA VLP vaccine offers an effective and safe strategy to create a prophylactic vaccine that protect against Zika infection as well as its serious effects such as microcephaly
The ideal purpose of the collaboration is to develop the translational study with TechnoVax by completing the Zika vaccine development and provoke new vaccine projects directed to other virus pathogens.
The trial has been accepted for publishing within the journal PLOS Neglected Tropical diseases.
According to the Centers for Disease Control and Prevention, Zika can spread by the bite of an infected Aedes mosquito. It may be passed from a pregnant female to her fetus. Infection while being pregnant can cause birth defects. There is no vaccine or medicine for Zika. Local mosquito-borne Zika virus transmission has been found within the United States.
What is Zika?
Discovered within the Zika woodland, Uganda, in 1947, Zika virus is a member of the flavivirus circle. Other flaviviruses include those that cause dengue, yellow fever, and West Nile fever. Like its family, Zika virus is more often transmitted to humans through infected Aedes aegypti mosquitoes. Zika virus may be transmitted from an infected pregnant woman to her child at some stage in pregnancy and may result in severe birth defects, together with microcephaly. Less generally, the virus can be spread via intercourse or blood transfusion. Most people who turn out to be infected with Zika virus do not become sick. For the 20 percent of folks who do have more symptoms, the contamination is generally slight and includes fever, rash, joint pain and conjunctivitis (red eyes). Illness lasts several days to per week. In non-pregnant females, the virus is normally removed from the body after a few weeks despite the fact that it can stay longer in semen.
No vaccine exists to prevent Zika. Zika virus is spread to people mainly through the bite of an infected mosquito.
Mosquitoes that spread Zika virus feed during the day, however they can also bite at night. The satisfactory manner to prevent Zika is to protect yourself from mosquito bites.
Currently, outbreaks are occurring in many nations and territories. Zika virus will spread and it is going to be difficult to determine how and in which the virus will spread through the years.
Protect yourself in the course of sex. Zika may be passed via sex from someone who has Zika to his or her sex companions. Studies are underway to find out how lengthy Zika remains within the semen and vaginal fluids of humans who have Zika, and how lengthy it is able to be passed to sex companions. We know that Zika can remain in semen longer than in different body fluids, together with vaginal fluids, urine, and blood.
Not having sex can put off the threat of having Zika from intercourse. Condoms can reduce the threat of getting Zika from intercourse. Condoms encompass male and woman condoms. To be effective, condoms must be used from start to finish, on every occasion all through vaginal, anal, and oral sex and the sharing of intercourse toys.